Laurie Toich, Assistant Editor

Pharmacists play a critical role in helping patients adhere to therapy.

Disrupting the circadian rhythm exacerbate multiple sclerosis symptoms.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Patients with multiple sclerosis who eat healthy could reduce their risk of severe disability by 20%.

Only 21% of HIV-positive individuals visited a health care provider within 2 weeks of release from jail or prison.

Only 38.3% of non-Hispanic minorities with psoriasis visited a dermatologist.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Tofacitinib (Xeljanz/Xeljanz XR) improves disease severity for patients with psoriatic arthritis.

Exercise may help to control symptoms and delay disease progression in patients with Parkinson’s disease.

An immunotherapy combination increased progression-free survival among patients with advanced renal cell carcinoma.

Top news of the day from across the healthcare landscape.

A commonly used blood pressure medication may also heighten the risk of developing skin cancer.

A combination of ramucirumab plus cisplatin and capecitabine did not improve survival in gastric cancer.

Increasing myelin production by targeting oligodendrocytes shows promise as a treatment for multiple sclerosis.

Voluntary male circumcision and starting antiretroviral therapy reduced new cases of HIV by 42% in vulnerable regions.

Top news of the day from across the health care landscape.

Prescription drug list prices outpaced the rate of inflation every year from 2006 to 2015.

Tisagenlecleucel (Kymriah) produced an overall response rate of 53% in patients with lymphoma.

A majority of patients with hemophilia B avoided joint bleeds after receiving gene therapy.

Long-acting pre-exposure prophylaxis may improve adherence to HIV treatment.

Liver cancer is the most common cancer caused by diabetes and obesity.

Top news of the day from across the healthcare landscape.

Top news of the day from across the health care landscape.

Officials with the FDA have approved the expanded use of mepolizumab (Nucala) for the treatment of adults with eosinophilic granulomatosis with polyangiitis (EGPA).

A proposed Sandoz biosimilar of pegfilgrastim (Neulasta) demonstrated biosimilarity to the reference biologic.

A high number of patients with eosinophilic granulomatosis treated with mepolizumab achieve remission within 24 weeks compared with placebo patients.

Patients taking hydrochlorothiazide may be 7 times more likely to develop squamous cell carcinoma.

The presence of a nerve protein in the blood may indicate the development of new T1 and T2 lesions resulting from multiple sclerosis.